Global Antibody Drugs Market

Antibody Drugs Comprehensive Study by Type (Monoclonal Antibodies, Antibody-Drug Conjugates, Polyclonal Antibodies), Application (Central Nervous System (CNS) Disorders, Cancers, Autoimmune Disorders, Cardiovascular Diseases) Players and Region - Global Market Outlook to 2028

Antibody Drugs Market by XX Submarkets | Forecast Years 2023-2028 | CAGR: 5.98%  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Antibody Drugs Market Scope
Antibody refers to a protein produced mainly by plasma cell in order to neutralize pathogens such as pathogenic bacteria and viruses. The Anti-drug conjugated are an important class of highly potent biopharmaceutical drugs designed as a targeted therapy for cancer-killing. These drugs are created by the use of modern scientific techniques. The rising incidence of Cancer and growing geriatric population is propelling the market for Antibody-Drug Conjugates (ADC).

According to AMA, the Global Antibody Drugs market is expected to see growth rate of 5.98%

Antibody drugs market is a fragmented market due to the presence of various players. Companies are focusing on developing innovative combinations and solutions to improve quality, enhances and promotes performance, along with try to incorporate latest technology. The companies are coming up with partnerships or agreements along with planning strategic activities such as partnerships, product launch, mergers, and acquisitions which will help them to sustain in the market and maintain their competitive edge. Research Analyst at AMA estimates that United States Players will contribute to the maximum growth of Global Antibody Drugs market throughout the predicted period.

Biogen Inc. (United States), Amgen Inc. (United States), Johnson & Johnson Inc. (United States), Seattle Genetics Inc. (United States), AbbVie Inc. (United States), ImmunoGen, Inc. (United States), Pfizer Inc. (United States), Roche Holding AG (Switzerland), F. Hoffmann-La Roche Ltd. (Switzerland), Merck KGaA (Germany) and Novartis AG (Switzerland) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research are Millennium Pharmaceuticals (United States), Concortis Biotherapeutics (United States), Agensys, Inc. (United States), Progenics Pharmaceuticals (United States), Oxford BioTherapeutics (United States) and Mersana Therapeutics (United States).

Segmentation Overview
The study have segmented the market of Global Antibody Drugs market by Type (Monoclonal Antibodies, Antibody-Drug Conjugates and Polyclonal Antibodies), by Application (Central Nervous System (CNS) Disorders, Cancers, Autoimmune Disorders and Cardiovascular Diseases) and Region with country level break-up.

On the basis of geography, the market of Antibody Drugs has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico).

Influencing Trend:
The Pharmaceutical Industry Is Undergoing a Change from Chemical Drugs to Protein Drugs, Increasing Sedentary Lifestyles and Research and Development in Antibody Drug

Market Growth Drivers:
Number of Products in the Late Pipeline Stage of Clinical Trials, Emergence Of Targeted and Combination Therapies and Rising Population of Baby-Boomers

Challenges:
ADCs are Highly Complex and Structurally Heterogeneous, Identification of Critical Quality Attributes To Determine Product Characteristics and Cost and Time Intensive Antibody Development Process

Restraints:
High Cost of Anti Drugs Limits Its Mass Adoption

Opportunities:
High Specificity and Low Immunogenicity, Protein Therapeutics Is Widely Used To Treat Various Life-Threatening Diseases, High Recent Improvements in Major Analytical Techniques for ADC and Rising In Stem Cell and Neurobiology Research

Market Leaders and their Expansionary Development Strategies
In December 19, 2022, Biogen Inc. signed agreement with Genentech, a member of the Roche Group. According to this agreement Biogen will have no payment obligations and will receive tiered royalties on potential net sales of glofitamab within the United States as part of the company’s long-standing collaboration on antibodies targeting CD20. This helped company to expand its presence in antibody drugs market
In July 2018, Daiichi Sankyo Company, Limited and Glycotope GmbH have inked a pact regarding the combination of Glycotope’s investigational tumor-associated TA-MUC1 antibody gatipotuzumab and Daiichi Sankyo’s proprietary ADC technology for developing gatipotuzumab antibody drug conjugate.
According to WHO, in 2015, around 570,000 women died owing to breast cancer globally, which are approximately 15% of all cancer deaths among women. Breast cancer is most frequent cancer among the women, and impacting around 1.5 million women every years.

Key Target Audience
Pharmaceutical and Biotechnology Companies, Life Sciences Companies, Academic Research Institutes, Government Institutes, Private Research Firms, Contract Research Organizations (CROs), Venture Capitalists and Investors and Others

About Approach
The research aims to propose a patent-based approach in searching for potential technology partners as a supporting tool for enabling open innovation. The study also proposes a systematic searching process of technology partners as a
preliminary step to select the emerging and key players that are involved in implementing market estimations. While patent analysis is employed to overcome the aforementioned data- and process-related limitations, as expenses occurred in that technology allows us to estimate the market size by evolving segments as target market from the total available market.

Report Objectives / Segmentation Covered

By Type
  • Monoclonal Antibodies
  • Antibody-Drug Conjugates
  • Polyclonal Antibodies
By Application
  • Central Nervous System (CNS) Disorders
  • Cancers
  • Autoimmune Disorders
  • Cardiovascular Diseases
By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Number of Products in the Late Pipeline Stage of Clinical Trials
      • 3.2.2. Emergence Of Targeted and Combination Therapies
      • 3.2.3. Rising Population of Baby-Boomers
    • 3.3. Market Challenges
      • 3.3.1. ADCs are Highly Complex and Structurally Heterogeneous
      • 3.3.2. Identification of Critical Quality Attributes To Determine Product Characteristics
      • 3.3.3. Cost and Time Intensive Antibody Development Process
    • 3.4. Market Trends
      • 3.4.1. The Pharmaceutical Industry Is Undergoing a Change from Chemical Drugs to Protein Drugs
      • 3.4.2. Increasing Sedentary Lifestyles
      • 3.4.3. Research and Development in Antibody Drug
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Antibody Drugs, by Type, Application and Region (value, volume and price ) (2017-2022)
    • 5.1. Introduction
    • 5.2. Global Antibody Drugs (Value)
      • 5.2.1. Global Antibody Drugs by: Type (Value)
        • 5.2.1.1. Monoclonal Antibodies
        • 5.2.1.2. Antibody-Drug Conjugates
        • 5.2.1.3. Polyclonal Antibodies
      • 5.2.2. Global Antibody Drugs by: Application (Value)
        • 5.2.2.1. Central Nervous System (CNS) Disorders
        • 5.2.2.2. Cancers
        • 5.2.2.3. Autoimmune Disorders
        • 5.2.2.4. Cardiovascular Diseases
      • 5.2.3. Global Antibody Drugs Region
        • 5.2.3.1. South America
          • 5.2.3.1.1. Brazil
          • 5.2.3.1.2. Argentina
          • 5.2.3.1.3. Rest of South America
        • 5.2.3.2. Asia Pacific
          • 5.2.3.2.1. China
          • 5.2.3.2.2. Japan
          • 5.2.3.2.3. India
          • 5.2.3.2.4. South Korea
          • 5.2.3.2.5. Taiwan
          • 5.2.3.2.6. Australia
          • 5.2.3.2.7. Rest of Asia-Pacific
        • 5.2.3.3. Europe
          • 5.2.3.3.1. Germany
          • 5.2.3.3.2. France
          • 5.2.3.3.3. Italy
          • 5.2.3.3.4. United Kingdom
          • 5.2.3.3.5. Netherlands
          • 5.2.3.3.6. Rest of Europe
        • 5.2.3.4. MEA
          • 5.2.3.4.1. Middle East
          • 5.2.3.4.2. Africa
        • 5.2.3.5. North America
          • 5.2.3.5.1. United States
          • 5.2.3.5.2. Canada
          • 5.2.3.5.3. Mexico
    • 5.3. Global Antibody Drugs (Volume)
      • 5.3.1. Global Antibody Drugs by: Type (Volume)
        • 5.3.1.1. Monoclonal Antibodies
        • 5.3.1.2. Antibody-Drug Conjugates
        • 5.3.1.3. Polyclonal Antibodies
      • 5.3.2. Global Antibody Drugs by: Application (Volume)
        • 5.3.2.1. Central Nervous System (CNS) Disorders
        • 5.3.2.2. Cancers
        • 5.3.2.3. Autoimmune Disorders
        • 5.3.2.4. Cardiovascular Diseases
      • 5.3.3. Global Antibody Drugs Region
        • 5.3.3.1. South America
          • 5.3.3.1.1. Brazil
          • 5.3.3.1.2. Argentina
          • 5.3.3.1.3. Rest of South America
        • 5.3.3.2. Asia Pacific
          • 5.3.3.2.1. China
          • 5.3.3.2.2. Japan
          • 5.3.3.2.3. India
          • 5.3.3.2.4. South Korea
          • 5.3.3.2.5. Taiwan
          • 5.3.3.2.6. Australia
          • 5.3.3.2.7. Rest of Asia-Pacific
        • 5.3.3.3. Europe
          • 5.3.3.3.1. Germany
          • 5.3.3.3.2. France
          • 5.3.3.3.3. Italy
          • 5.3.3.3.4. United Kingdom
          • 5.3.3.3.5. Netherlands
          • 5.3.3.3.6. Rest of Europe
        • 5.3.3.4. MEA
          • 5.3.3.4.1. Middle East
          • 5.3.3.4.2. Africa
        • 5.3.3.5. North America
          • 5.3.3.5.1. United States
          • 5.3.3.5.2. Canada
          • 5.3.3.5.3. Mexico
    • 5.4. Global Antibody Drugs (Price)
      • 5.4.1. Global Antibody Drugs by: Type (Price)
  • 6. Antibody Drugs: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2022)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Biogen Inc. (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Amgen Inc. (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Johnson & Johnson Inc. (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Seattle Genetics Inc. (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. AbbVie Inc. (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. ImmunoGen, Inc. (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Pfizer Inc. (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Roche Holding AG (Switzerland)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. F. Hoffmann-La Roche Ltd. (Switzerland)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Merck KGaA (Germany)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
      • 6.4.11. Novartis AG (Switzerland)
        • 6.4.11.1. Business Overview
        • 6.4.11.2. Products/Services Offerings
        • 6.4.11.3. Financial Analysis
        • 6.4.11.4. SWOT Analysis
  • 7. Global Antibody Drugs Sale, by Type, Application and Region (value, volume and price ) (2023-2028)
    • 7.1. Introduction
    • 7.2. Global Antibody Drugs (Value)
      • 7.2.1. Global Antibody Drugs by: Type (Value)
        • 7.2.1.1. Monoclonal Antibodies
        • 7.2.1.2. Antibody-Drug Conjugates
        • 7.2.1.3. Polyclonal Antibodies
      • 7.2.2. Global Antibody Drugs by: Application (Value)
        • 7.2.2.1. Central Nervous System (CNS) Disorders
        • 7.2.2.2. Cancers
        • 7.2.2.3. Autoimmune Disorders
        • 7.2.2.4. Cardiovascular Diseases
      • 7.2.3. Global Antibody Drugs Region
        • 7.2.3.1. South America
          • 7.2.3.1.1. Brazil
          • 7.2.3.1.2. Argentina
          • 7.2.3.1.3. Rest of South America
        • 7.2.3.2. Asia Pacific
          • 7.2.3.2.1. China
          • 7.2.3.2.2. Japan
          • 7.2.3.2.3. India
          • 7.2.3.2.4. South Korea
          • 7.2.3.2.5. Taiwan
          • 7.2.3.2.6. Australia
          • 7.2.3.2.7. Rest of Asia-Pacific
        • 7.2.3.3. Europe
          • 7.2.3.3.1. Germany
          • 7.2.3.3.2. France
          • 7.2.3.3.3. Italy
          • 7.2.3.3.4. United Kingdom
          • 7.2.3.3.5. Netherlands
          • 7.2.3.3.6. Rest of Europe
        • 7.2.3.4. MEA
          • 7.2.3.4.1. Middle East
          • 7.2.3.4.2. Africa
        • 7.2.3.5. North America
          • 7.2.3.5.1. United States
          • 7.2.3.5.2. Canada
          • 7.2.3.5.3. Mexico
    • 7.3. Global Antibody Drugs (Volume)
      • 7.3.1. Global Antibody Drugs by: Type (Volume)
        • 7.3.1.1. Monoclonal Antibodies
        • 7.3.1.2. Antibody-Drug Conjugates
        • 7.3.1.3. Polyclonal Antibodies
      • 7.3.2. Global Antibody Drugs by: Application (Volume)
        • 7.3.2.1. Central Nervous System (CNS) Disorders
        • 7.3.2.2. Cancers
        • 7.3.2.3. Autoimmune Disorders
        • 7.3.2.4. Cardiovascular Diseases
      • 7.3.3. Global Antibody Drugs Region
        • 7.3.3.1. South America
          • 7.3.3.1.1. Brazil
          • 7.3.3.1.2. Argentina
          • 7.3.3.1.3. Rest of South America
        • 7.3.3.2. Asia Pacific
          • 7.3.3.2.1. China
          • 7.3.3.2.2. Japan
          • 7.3.3.2.3. India
          • 7.3.3.2.4. South Korea
          • 7.3.3.2.5. Taiwan
          • 7.3.3.2.6. Australia
          • 7.3.3.2.7. Rest of Asia-Pacific
        • 7.3.3.3. Europe
          • 7.3.3.3.1. Germany
          • 7.3.3.3.2. France
          • 7.3.3.3.3. Italy
          • 7.3.3.3.4. United Kingdom
          • 7.3.3.3.5. Netherlands
          • 7.3.3.3.6. Rest of Europe
        • 7.3.3.4. MEA
          • 7.3.3.4.1. Middle East
          • 7.3.3.4.2. Africa
        • 7.3.3.5. North America
          • 7.3.3.5.1. United States
          • 7.3.3.5.2. Canada
          • 7.3.3.5.3. Mexico
    • 7.4. Global Antibody Drugs (Price)
      • 7.4.1. Global Antibody Drugs by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Antibody Drugs: by Type(USD Million)
  • Table 2. Antibody Drugs Monoclonal Antibodies , by Region USD Million (2017-2022)
  • Table 3. Antibody Drugs Antibody-Drug Conjugates , by Region USD Million (2017-2022)
  • Table 4. Antibody Drugs Polyclonal Antibodies , by Region USD Million (2017-2022)
  • Table 5. Antibody Drugs: by Application(USD Million)
  • Table 6. Antibody Drugs Central Nervous System (CNS) Disorders , by Region USD Million (2017-2022)
  • Table 7. Antibody Drugs Cancers , by Region USD Million (2017-2022)
  • Table 8. Antibody Drugs Autoimmune Disorders , by Region USD Million (2017-2022)
  • Table 9. Antibody Drugs Cardiovascular Diseases , by Region USD Million (2017-2022)
  • Table 10. South America Antibody Drugs, by Country USD Million (2017-2022)
  • Table 11. South America Antibody Drugs, by Type USD Million (2017-2022)
  • Table 12. South America Antibody Drugs, by Application USD Million (2017-2022)
  • Table 13. Brazil Antibody Drugs, by Type USD Million (2017-2022)
  • Table 14. Brazil Antibody Drugs, by Application USD Million (2017-2022)
  • Table 15. Argentina Antibody Drugs, by Type USD Million (2017-2022)
  • Table 16. Argentina Antibody Drugs, by Application USD Million (2017-2022)
  • Table 17. Rest of South America Antibody Drugs, by Type USD Million (2017-2022)
  • Table 18. Rest of South America Antibody Drugs, by Application USD Million (2017-2022)
  • Table 19. Asia Pacific Antibody Drugs, by Country USD Million (2017-2022)
  • Table 20. Asia Pacific Antibody Drugs, by Type USD Million (2017-2022)
  • Table 21. Asia Pacific Antibody Drugs, by Application USD Million (2017-2022)
  • Table 22. China Antibody Drugs, by Type USD Million (2017-2022)
  • Table 23. China Antibody Drugs, by Application USD Million (2017-2022)
  • Table 24. Japan Antibody Drugs, by Type USD Million (2017-2022)
  • Table 25. Japan Antibody Drugs, by Application USD Million (2017-2022)
  • Table 26. India Antibody Drugs, by Type USD Million (2017-2022)
  • Table 27. India Antibody Drugs, by Application USD Million (2017-2022)
  • Table 28. South Korea Antibody Drugs, by Type USD Million (2017-2022)
  • Table 29. South Korea Antibody Drugs, by Application USD Million (2017-2022)
  • Table 30. Taiwan Antibody Drugs, by Type USD Million (2017-2022)
  • Table 31. Taiwan Antibody Drugs, by Application USD Million (2017-2022)
  • Table 32. Australia Antibody Drugs, by Type USD Million (2017-2022)
  • Table 33. Australia Antibody Drugs, by Application USD Million (2017-2022)
  • Table 34. Rest of Asia-Pacific Antibody Drugs, by Type USD Million (2017-2022)
  • Table 35. Rest of Asia-Pacific Antibody Drugs, by Application USD Million (2017-2022)
  • Table 36. Europe Antibody Drugs, by Country USD Million (2017-2022)
  • Table 37. Europe Antibody Drugs, by Type USD Million (2017-2022)
  • Table 38. Europe Antibody Drugs, by Application USD Million (2017-2022)
  • Table 39. Germany Antibody Drugs, by Type USD Million (2017-2022)
  • Table 40. Germany Antibody Drugs, by Application USD Million (2017-2022)
  • Table 41. France Antibody Drugs, by Type USD Million (2017-2022)
  • Table 42. France Antibody Drugs, by Application USD Million (2017-2022)
  • Table 43. Italy Antibody Drugs, by Type USD Million (2017-2022)
  • Table 44. Italy Antibody Drugs, by Application USD Million (2017-2022)
  • Table 45. United Kingdom Antibody Drugs, by Type USD Million (2017-2022)
  • Table 46. United Kingdom Antibody Drugs, by Application USD Million (2017-2022)
  • Table 47. Netherlands Antibody Drugs, by Type USD Million (2017-2022)
  • Table 48. Netherlands Antibody Drugs, by Application USD Million (2017-2022)
  • Table 49. Rest of Europe Antibody Drugs, by Type USD Million (2017-2022)
  • Table 50. Rest of Europe Antibody Drugs, by Application USD Million (2017-2022)
  • Table 51. MEA Antibody Drugs, by Country USD Million (2017-2022)
  • Table 52. MEA Antibody Drugs, by Type USD Million (2017-2022)
  • Table 53. MEA Antibody Drugs, by Application USD Million (2017-2022)
  • Table 54. Middle East Antibody Drugs, by Type USD Million (2017-2022)
  • Table 55. Middle East Antibody Drugs, by Application USD Million (2017-2022)
  • Table 56. Africa Antibody Drugs, by Type USD Million (2017-2022)
  • Table 57. Africa Antibody Drugs, by Application USD Million (2017-2022)
  • Table 58. North America Antibody Drugs, by Country USD Million (2017-2022)
  • Table 59. North America Antibody Drugs, by Type USD Million (2017-2022)
  • Table 60. North America Antibody Drugs, by Application USD Million (2017-2022)
  • Table 61. United States Antibody Drugs, by Type USD Million (2017-2022)
  • Table 62. United States Antibody Drugs, by Application USD Million (2017-2022)
  • Table 63. Canada Antibody Drugs, by Type USD Million (2017-2022)
  • Table 64. Canada Antibody Drugs, by Application USD Million (2017-2022)
  • Table 65. Mexico Antibody Drugs, by Type USD Million (2017-2022)
  • Table 66. Mexico Antibody Drugs, by Application USD Million (2017-2022)
  • Table 67. Antibody Drugs Sales: by Type(K Tons)
  • Table 68. Antibody Drugs Sales Monoclonal Antibodies , by Region K Tons (2017-2022)
  • Table 69. Antibody Drugs Sales Antibody-Drug Conjugates , by Region K Tons (2017-2022)
  • Table 70. Antibody Drugs Sales Polyclonal Antibodies , by Region K Tons (2017-2022)
  • Table 71. Antibody Drugs Sales: by Application(K Tons)
  • Table 72. Antibody Drugs Sales Central Nervous System (CNS) Disorders , by Region K Tons (2017-2022)
  • Table 73. Antibody Drugs Sales Cancers , by Region K Tons (2017-2022)
  • Table 74. Antibody Drugs Sales Autoimmune Disorders , by Region K Tons (2017-2022)
  • Table 75. Antibody Drugs Sales Cardiovascular Diseases , by Region K Tons (2017-2022)
  • Table 76. South America Antibody Drugs Sales, by Country K Tons (2017-2022)
  • Table 77. South America Antibody Drugs Sales, by Type K Tons (2017-2022)
  • Table 78. South America Antibody Drugs Sales, by Application K Tons (2017-2022)
  • Table 79. Brazil Antibody Drugs Sales, by Type K Tons (2017-2022)
  • Table 80. Brazil Antibody Drugs Sales, by Application K Tons (2017-2022)
  • Table 81. Argentina Antibody Drugs Sales, by Type K Tons (2017-2022)
  • Table 82. Argentina Antibody Drugs Sales, by Application K Tons (2017-2022)
  • Table 83. Rest of South America Antibody Drugs Sales, by Type K Tons (2017-2022)
  • Table 84. Rest of South America Antibody Drugs Sales, by Application K Tons (2017-2022)
  • Table 85. Asia Pacific Antibody Drugs Sales, by Country K Tons (2017-2022)
  • Table 86. Asia Pacific Antibody Drugs Sales, by Type K Tons (2017-2022)
  • Table 87. Asia Pacific Antibody Drugs Sales, by Application K Tons (2017-2022)
  • Table 88. China Antibody Drugs Sales, by Type K Tons (2017-2022)
  • Table 89. China Antibody Drugs Sales, by Application K Tons (2017-2022)
  • Table 90. Japan Antibody Drugs Sales, by Type K Tons (2017-2022)
  • Table 91. Japan Antibody Drugs Sales, by Application K Tons (2017-2022)
  • Table 92. India Antibody Drugs Sales, by Type K Tons (2017-2022)
  • Table 93. India Antibody Drugs Sales, by Application K Tons (2017-2022)
  • Table 94. South Korea Antibody Drugs Sales, by Type K Tons (2017-2022)
  • Table 95. South Korea Antibody Drugs Sales, by Application K Tons (2017-2022)
  • Table 96. Taiwan Antibody Drugs Sales, by Type K Tons (2017-2022)
  • Table 97. Taiwan Antibody Drugs Sales, by Application K Tons (2017-2022)
  • Table 98. Australia Antibody Drugs Sales, by Type K Tons (2017-2022)
  • Table 99. Australia Antibody Drugs Sales, by Application K Tons (2017-2022)
  • Table 100. Rest of Asia-Pacific Antibody Drugs Sales, by Type K Tons (2017-2022)
  • Table 101. Rest of Asia-Pacific Antibody Drugs Sales, by Application K Tons (2017-2022)
  • Table 102. Europe Antibody Drugs Sales, by Country K Tons (2017-2022)
  • Table 103. Europe Antibody Drugs Sales, by Type K Tons (2017-2022)
  • Table 104. Europe Antibody Drugs Sales, by Application K Tons (2017-2022)
  • Table 105. Germany Antibody Drugs Sales, by Type K Tons (2017-2022)
  • Table 106. Germany Antibody Drugs Sales, by Application K Tons (2017-2022)
  • Table 107. France Antibody Drugs Sales, by Type K Tons (2017-2022)
  • Table 108. France Antibody Drugs Sales, by Application K Tons (2017-2022)
  • Table 109. Italy Antibody Drugs Sales, by Type K Tons (2017-2022)
  • Table 110. Italy Antibody Drugs Sales, by Application K Tons (2017-2022)
  • Table 111. United Kingdom Antibody Drugs Sales, by Type K Tons (2017-2022)
  • Table 112. United Kingdom Antibody Drugs Sales, by Application K Tons (2017-2022)
  • Table 113. Netherlands Antibody Drugs Sales, by Type K Tons (2017-2022)
  • Table 114. Netherlands Antibody Drugs Sales, by Application K Tons (2017-2022)
  • Table 115. Rest of Europe Antibody Drugs Sales, by Type K Tons (2017-2022)
  • Table 116. Rest of Europe Antibody Drugs Sales, by Application K Tons (2017-2022)
  • Table 117. MEA Antibody Drugs Sales, by Country K Tons (2017-2022)
  • Table 118. MEA Antibody Drugs Sales, by Type K Tons (2017-2022)
  • Table 119. MEA Antibody Drugs Sales, by Application K Tons (2017-2022)
  • Table 120. Middle East Antibody Drugs Sales, by Type K Tons (2017-2022)
  • Table 121. Middle East Antibody Drugs Sales, by Application K Tons (2017-2022)
  • Table 122. Africa Antibody Drugs Sales, by Type K Tons (2017-2022)
  • Table 123. Africa Antibody Drugs Sales, by Application K Tons (2017-2022)
  • Table 124. North America Antibody Drugs Sales, by Country K Tons (2017-2022)
  • Table 125. North America Antibody Drugs Sales, by Type K Tons (2017-2022)
  • Table 126. North America Antibody Drugs Sales, by Application K Tons (2017-2022)
  • Table 127. United States Antibody Drugs Sales, by Type K Tons (2017-2022)
  • Table 128. United States Antibody Drugs Sales, by Application K Tons (2017-2022)
  • Table 129. Canada Antibody Drugs Sales, by Type K Tons (2017-2022)
  • Table 130. Canada Antibody Drugs Sales, by Application K Tons (2017-2022)
  • Table 131. Mexico Antibody Drugs Sales, by Type K Tons (2017-2022)
  • Table 132. Mexico Antibody Drugs Sales, by Application K Tons (2017-2022)
  • Table 133. Antibody Drugs: by Type(USD/Units)
  • Table 134. Company Basic Information, Sales Area and Its Competitors
  • Table 135. Company Basic Information, Sales Area and Its Competitors
  • Table 136. Company Basic Information, Sales Area and Its Competitors
  • Table 137. Company Basic Information, Sales Area and Its Competitors
  • Table 138. Company Basic Information, Sales Area and Its Competitors
  • Table 139. Company Basic Information, Sales Area and Its Competitors
  • Table 140. Company Basic Information, Sales Area and Its Competitors
  • Table 141. Company Basic Information, Sales Area and Its Competitors
  • Table 142. Company Basic Information, Sales Area and Its Competitors
  • Table 143. Company Basic Information, Sales Area and Its Competitors
  • Table 144. Company Basic Information, Sales Area and Its Competitors
  • Table 145. Antibody Drugs: by Type(USD Million)
  • Table 146. Antibody Drugs Monoclonal Antibodies , by Region USD Million (2023-2028)
  • Table 147. Antibody Drugs Antibody-Drug Conjugates , by Region USD Million (2023-2028)
  • Table 148. Antibody Drugs Polyclonal Antibodies , by Region USD Million (2023-2028)
  • Table 149. Antibody Drugs: by Application(USD Million)
  • Table 150. Antibody Drugs Central Nervous System (CNS) Disorders , by Region USD Million (2023-2028)
  • Table 151. Antibody Drugs Cancers , by Region USD Million (2023-2028)
  • Table 152. Antibody Drugs Autoimmune Disorders , by Region USD Million (2023-2028)
  • Table 153. Antibody Drugs Cardiovascular Diseases , by Region USD Million (2023-2028)
  • Table 154. South America Antibody Drugs, by Country USD Million (2023-2028)
  • Table 155. South America Antibody Drugs, by Type USD Million (2023-2028)
  • Table 156. South America Antibody Drugs, by Application USD Million (2023-2028)
  • Table 157. Brazil Antibody Drugs, by Type USD Million (2023-2028)
  • Table 158. Brazil Antibody Drugs, by Application USD Million (2023-2028)
  • Table 159. Argentina Antibody Drugs, by Type USD Million (2023-2028)
  • Table 160. Argentina Antibody Drugs, by Application USD Million (2023-2028)
  • Table 161. Rest of South America Antibody Drugs, by Type USD Million (2023-2028)
  • Table 162. Rest of South America Antibody Drugs, by Application USD Million (2023-2028)
  • Table 163. Asia Pacific Antibody Drugs, by Country USD Million (2023-2028)
  • Table 164. Asia Pacific Antibody Drugs, by Type USD Million (2023-2028)
  • Table 165. Asia Pacific Antibody Drugs, by Application USD Million (2023-2028)
  • Table 166. China Antibody Drugs, by Type USD Million (2023-2028)
  • Table 167. China Antibody Drugs, by Application USD Million (2023-2028)
  • Table 168. Japan Antibody Drugs, by Type USD Million (2023-2028)
  • Table 169. Japan Antibody Drugs, by Application USD Million (2023-2028)
  • Table 170. India Antibody Drugs, by Type USD Million (2023-2028)
  • Table 171. India Antibody Drugs, by Application USD Million (2023-2028)
  • Table 172. South Korea Antibody Drugs, by Type USD Million (2023-2028)
  • Table 173. South Korea Antibody Drugs, by Application USD Million (2023-2028)
  • Table 174. Taiwan Antibody Drugs, by Type USD Million (2023-2028)
  • Table 175. Taiwan Antibody Drugs, by Application USD Million (2023-2028)
  • Table 176. Australia Antibody Drugs, by Type USD Million (2023-2028)
  • Table 177. Australia Antibody Drugs, by Application USD Million (2023-2028)
  • Table 178. Rest of Asia-Pacific Antibody Drugs, by Type USD Million (2023-2028)
  • Table 179. Rest of Asia-Pacific Antibody Drugs, by Application USD Million (2023-2028)
  • Table 180. Europe Antibody Drugs, by Country USD Million (2023-2028)
  • Table 181. Europe Antibody Drugs, by Type USD Million (2023-2028)
  • Table 182. Europe Antibody Drugs, by Application USD Million (2023-2028)
  • Table 183. Germany Antibody Drugs, by Type USD Million (2023-2028)
  • Table 184. Germany Antibody Drugs, by Application USD Million (2023-2028)
  • Table 185. France Antibody Drugs, by Type USD Million (2023-2028)
  • Table 186. France Antibody Drugs, by Application USD Million (2023-2028)
  • Table 187. Italy Antibody Drugs, by Type USD Million (2023-2028)
  • Table 188. Italy Antibody Drugs, by Application USD Million (2023-2028)
  • Table 189. United Kingdom Antibody Drugs, by Type USD Million (2023-2028)
  • Table 190. United Kingdom Antibody Drugs, by Application USD Million (2023-2028)
  • Table 191. Netherlands Antibody Drugs, by Type USD Million (2023-2028)
  • Table 192. Netherlands Antibody Drugs, by Application USD Million (2023-2028)
  • Table 193. Rest of Europe Antibody Drugs, by Type USD Million (2023-2028)
  • Table 194. Rest of Europe Antibody Drugs, by Application USD Million (2023-2028)
  • Table 195. MEA Antibody Drugs, by Country USD Million (2023-2028)
  • Table 196. MEA Antibody Drugs, by Type USD Million (2023-2028)
  • Table 197. MEA Antibody Drugs, by Application USD Million (2023-2028)
  • Table 198. Middle East Antibody Drugs, by Type USD Million (2023-2028)
  • Table 199. Middle East Antibody Drugs, by Application USD Million (2023-2028)
  • Table 200. Africa Antibody Drugs, by Type USD Million (2023-2028)
  • Table 201. Africa Antibody Drugs, by Application USD Million (2023-2028)
  • Table 202. North America Antibody Drugs, by Country USD Million (2023-2028)
  • Table 203. North America Antibody Drugs, by Type USD Million (2023-2028)
  • Table 204. North America Antibody Drugs, by Application USD Million (2023-2028)
  • Table 205. United States Antibody Drugs, by Type USD Million (2023-2028)
  • Table 206. United States Antibody Drugs, by Application USD Million (2023-2028)
  • Table 207. Canada Antibody Drugs, by Type USD Million (2023-2028)
  • Table 208. Canada Antibody Drugs, by Application USD Million (2023-2028)
  • Table 209. Mexico Antibody Drugs, by Type USD Million (2023-2028)
  • Table 210. Mexico Antibody Drugs, by Application USD Million (2023-2028)
  • Table 211. Antibody Drugs Sales: by Type(K Tons)
  • Table 212. Antibody Drugs Sales Monoclonal Antibodies , by Region K Tons (2023-2028)
  • Table 213. Antibody Drugs Sales Antibody-Drug Conjugates , by Region K Tons (2023-2028)
  • Table 214. Antibody Drugs Sales Polyclonal Antibodies , by Region K Tons (2023-2028)
  • Table 215. Antibody Drugs Sales: by Application(K Tons)
  • Table 216. Antibody Drugs Sales Central Nervous System (CNS) Disorders , by Region K Tons (2023-2028)
  • Table 217. Antibody Drugs Sales Cancers , by Region K Tons (2023-2028)
  • Table 218. Antibody Drugs Sales Autoimmune Disorders , by Region K Tons (2023-2028)
  • Table 219. Antibody Drugs Sales Cardiovascular Diseases , by Region K Tons (2023-2028)
  • Table 220. South America Antibody Drugs Sales, by Country K Tons (2023-2028)
  • Table 221. South America Antibody Drugs Sales, by Type K Tons (2023-2028)
  • Table 222. South America Antibody Drugs Sales, by Application K Tons (2023-2028)
  • Table 223. Brazil Antibody Drugs Sales, by Type K Tons (2023-2028)
  • Table 224. Brazil Antibody Drugs Sales, by Application K Tons (2023-2028)
  • Table 225. Argentina Antibody Drugs Sales, by Type K Tons (2023-2028)
  • Table 226. Argentina Antibody Drugs Sales, by Application K Tons (2023-2028)
  • Table 227. Rest of South America Antibody Drugs Sales, by Type K Tons (2023-2028)
  • Table 228. Rest of South America Antibody Drugs Sales, by Application K Tons (2023-2028)
  • Table 229. Asia Pacific Antibody Drugs Sales, by Country K Tons (2023-2028)
  • Table 230. Asia Pacific Antibody Drugs Sales, by Type K Tons (2023-2028)
  • Table 231. Asia Pacific Antibody Drugs Sales, by Application K Tons (2023-2028)
  • Table 232. China Antibody Drugs Sales, by Type K Tons (2023-2028)
  • Table 233. China Antibody Drugs Sales, by Application K Tons (2023-2028)
  • Table 234. Japan Antibody Drugs Sales, by Type K Tons (2023-2028)
  • Table 235. Japan Antibody Drugs Sales, by Application K Tons (2023-2028)
  • Table 236. India Antibody Drugs Sales, by Type K Tons (2023-2028)
  • Table 237. India Antibody Drugs Sales, by Application K Tons (2023-2028)
  • Table 238. South Korea Antibody Drugs Sales, by Type K Tons (2023-2028)
  • Table 239. South Korea Antibody Drugs Sales, by Application K Tons (2023-2028)
  • Table 240. Taiwan Antibody Drugs Sales, by Type K Tons (2023-2028)
  • Table 241. Taiwan Antibody Drugs Sales, by Application K Tons (2023-2028)
  • Table 242. Australia Antibody Drugs Sales, by Type K Tons (2023-2028)
  • Table 243. Australia Antibody Drugs Sales, by Application K Tons (2023-2028)
  • Table 244. Rest of Asia-Pacific Antibody Drugs Sales, by Type K Tons (2023-2028)
  • Table 245. Rest of Asia-Pacific Antibody Drugs Sales, by Application K Tons (2023-2028)
  • Table 246. Europe Antibody Drugs Sales, by Country K Tons (2023-2028)
  • Table 247. Europe Antibody Drugs Sales, by Type K Tons (2023-2028)
  • Table 248. Europe Antibody Drugs Sales, by Application K Tons (2023-2028)
  • Table 249. Germany Antibody Drugs Sales, by Type K Tons (2023-2028)
  • Table 250. Germany Antibody Drugs Sales, by Application K Tons (2023-2028)
  • Table 251. France Antibody Drugs Sales, by Type K Tons (2023-2028)
  • Table 252. France Antibody Drugs Sales, by Application K Tons (2023-2028)
  • Table 253. Italy Antibody Drugs Sales, by Type K Tons (2023-2028)
  • Table 254. Italy Antibody Drugs Sales, by Application K Tons (2023-2028)
  • Table 255. United Kingdom Antibody Drugs Sales, by Type K Tons (2023-2028)
  • Table 256. United Kingdom Antibody Drugs Sales, by Application K Tons (2023-2028)
  • Table 257. Netherlands Antibody Drugs Sales, by Type K Tons (2023-2028)
  • Table 258. Netherlands Antibody Drugs Sales, by Application K Tons (2023-2028)
  • Table 259. Rest of Europe Antibody Drugs Sales, by Type K Tons (2023-2028)
  • Table 260. Rest of Europe Antibody Drugs Sales, by Application K Tons (2023-2028)
  • Table 261. MEA Antibody Drugs Sales, by Country K Tons (2023-2028)
  • Table 262. MEA Antibody Drugs Sales, by Type K Tons (2023-2028)
  • Table 263. MEA Antibody Drugs Sales, by Application K Tons (2023-2028)
  • Table 264. Middle East Antibody Drugs Sales, by Type K Tons (2023-2028)
  • Table 265. Middle East Antibody Drugs Sales, by Application K Tons (2023-2028)
  • Table 266. Africa Antibody Drugs Sales, by Type K Tons (2023-2028)
  • Table 267. Africa Antibody Drugs Sales, by Application K Tons (2023-2028)
  • Table 268. North America Antibody Drugs Sales, by Country K Tons (2023-2028)
  • Table 269. North America Antibody Drugs Sales, by Type K Tons (2023-2028)
  • Table 270. North America Antibody Drugs Sales, by Application K Tons (2023-2028)
  • Table 271. United States Antibody Drugs Sales, by Type K Tons (2023-2028)
  • Table 272. United States Antibody Drugs Sales, by Application K Tons (2023-2028)
  • Table 273. Canada Antibody Drugs Sales, by Type K Tons (2023-2028)
  • Table 274. Canada Antibody Drugs Sales, by Application K Tons (2023-2028)
  • Table 275. Mexico Antibody Drugs Sales, by Type K Tons (2023-2028)
  • Table 276. Mexico Antibody Drugs Sales, by Application K Tons (2023-2028)
  • Table 277. Antibody Drugs: by Type(USD/Units)
  • Table 278. Research Programs/Design for This Report
  • Table 279. Key Data Information from Secondary Sources
  • Table 280. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Antibody Drugs: by Type USD Million (2017-2022)
  • Figure 5. Global Antibody Drugs: by Application USD Million (2017-2022)
  • Figure 6. South America Antibody Drugs Share (%), by Country
  • Figure 7. Asia Pacific Antibody Drugs Share (%), by Country
  • Figure 8. Europe Antibody Drugs Share (%), by Country
  • Figure 9. MEA Antibody Drugs Share (%), by Country
  • Figure 10. North America Antibody Drugs Share (%), by Country
  • Figure 11. Global Antibody Drugs: by Type K Tons (2017-2022)
  • Figure 12. Global Antibody Drugs: by Application K Tons (2017-2022)
  • Figure 13. South America Antibody Drugs Share (%), by Country
  • Figure 14. Asia Pacific Antibody Drugs Share (%), by Country
  • Figure 15. Europe Antibody Drugs Share (%), by Country
  • Figure 16. MEA Antibody Drugs Share (%), by Country
  • Figure 17. North America Antibody Drugs Share (%), by Country
  • Figure 18. Global Antibody Drugs: by Type USD/Units (2017-2022)
  • Figure 19. Global Antibody Drugs share by Players 2022 (%)
  • Figure 20. Global Antibody Drugs share by Players (Top 3) 2022(%)
  • Figure 21. Global Antibody Drugs share by Players (Top 5) 2022(%)
  • Figure 22. BCG Matrix for key Companies
  • Figure 23. Biogen Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 24. Biogen Inc. (United States) Revenue: by Geography 2022
  • Figure 25. Amgen Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 26. Amgen Inc. (United States) Revenue: by Geography 2022
  • Figure 27. Johnson & Johnson Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 28. Johnson & Johnson Inc. (United States) Revenue: by Geography 2022
  • Figure 29. Seattle Genetics Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 30. Seattle Genetics Inc. (United States) Revenue: by Geography 2022
  • Figure 31. AbbVie Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 32. AbbVie Inc. (United States) Revenue: by Geography 2022
  • Figure 33. ImmunoGen, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 34. ImmunoGen, Inc. (United States) Revenue: by Geography 2022
  • Figure 35. Pfizer Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 36. Pfizer Inc. (United States) Revenue: by Geography 2022
  • Figure 37. Roche Holding AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 38. Roche Holding AG (Switzerland) Revenue: by Geography 2022
  • Figure 39. F. Hoffmann-La Roche Ltd. (Switzerland) Revenue, Net Income and Gross profit
  • Figure 40. F. Hoffmann-La Roche Ltd. (Switzerland) Revenue: by Geography 2022
  • Figure 41. Merck KGaA (Germany) Revenue, Net Income and Gross profit
  • Figure 42. Merck KGaA (Germany) Revenue: by Geography 2022
  • Figure 43. Novartis AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 44. Novartis AG (Switzerland) Revenue: by Geography 2022
  • Figure 45. Global Antibody Drugs: by Type USD Million (2023-2028)
  • Figure 46. Global Antibody Drugs: by Application USD Million (2023-2028)
  • Figure 47. South America Antibody Drugs Share (%), by Country
  • Figure 48. Asia Pacific Antibody Drugs Share (%), by Country
  • Figure 49. Europe Antibody Drugs Share (%), by Country
  • Figure 50. MEA Antibody Drugs Share (%), by Country
  • Figure 51. North America Antibody Drugs Share (%), by Country
  • Figure 52. Global Antibody Drugs: by Type K Tons (2023-2028)
  • Figure 53. Global Antibody Drugs: by Application K Tons (2023-2028)
  • Figure 54. South America Antibody Drugs Share (%), by Country
  • Figure 55. Asia Pacific Antibody Drugs Share (%), by Country
  • Figure 56. Europe Antibody Drugs Share (%), by Country
  • Figure 57. MEA Antibody Drugs Share (%), by Country
  • Figure 58. North America Antibody Drugs Share (%), by Country
  • Figure 59. Global Antibody Drugs: by Type USD/Units (2023-2028)
List of companies from research coverage that are profiled in the study
  • Biogen Inc. (United States)
  • Amgen Inc. (United States)
  • Johnson & Johnson Inc. (United States)
  • Seattle Genetics Inc. (United States)
  • AbbVie Inc. (United States)
  • ImmunoGen, Inc. (United States)
  • Pfizer Inc. (United States)
  • Roche Holding AG (Switzerland)
  • F. Hoffmann-La Roche Ltd. (Switzerland)
  • Merck KGaA (Germany)
  • Novartis AG (Switzerland)
Additional players considered in the study are as follows:
Millennium Pharmaceuticals (United States) , Concortis Biotherapeutics (United States) , Agensys, Inc. (United States) , Progenics Pharmaceuticals (United States) , Oxford BioTherapeutics (United States) , Mersana Therapeutics (United States)
Select User Access Type

Key Highlights of Report


Jun 2023 243 Pages 67 Tables Base Year: 2022 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Antibody Drugs Market Quantitative research analysis
Global Antibody Drugs Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The Antibody Drugs study can be customized to meet your requirements. The market size breakdown by type, by end-use application.
The Antibody Drugs Market is gaining popularity and expected to see strong valuation by 2028 and may reach USD 132.47 Million .
According to AMA, the Global Antibody Drugs market is expected to see growth rate of xx%.
The Antibody Drugs market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get a complete of companies available in our research coverage.

Know More About Global Antibody Drugs Market Report?

Have a Query? Click Here

Other Related Reports

Capsule Shell Comprehensive Study by Type (Gelatin Capsule (Hard Gelatin Capsule, Soft Gelatin Capsule), Non-Gelatin Capsule), Application (Antibiotic Drugs, Vitamin and Dietary Supplements, Antacid ...
$ 3750
Diarrhea Drug Comprehensive Study by Type (Adult, Children), Application (Family, Hospital), Form (Syringe, Tablets), Dosage (10 mg, 15 mg, 20 mg, 30 mg) Players and Region - Global Market Outlook to...
$ 3500
Caspase 3 Comprehensive Study by Type (1G3-Cu, BaxM-159, Emricasan, IDN-7314, Others), Application (Liver Cirrhosis, Liver Failure, Pulmonary Fibrosis, Solid Tumor, Others) Players and Region - Globa...
$ 3400
Docetaxel Comprehensive Study by Type (40 mg/ml, 20 mg/ml, 10 mg/ml), Application (Breast Cancer, Non-Small Cell Lung Cancer, Prostate Cancer, Gastric Adenocarcinoma Cancer, Head and Neck Cancer), En...
$ 3650
Doxorubicin Comprehensive Study by Type (Lyophilized Powder, Doxorubicin Injection), Application (Ovarian, Multiple Myeloma, Kaposi Sarcoma, Leukemia, Bone Sarcoma, Breast Cancer, Gastric Cancer, Oth...
$ 3450
Bone Substitutes Comprehensive Study by Type (Bone Grafts {Autograft, Allograft, Xenograft}, Ceramics {Hydroxyapatite, Tricalcium Phosphate (TCP), Calcium Sulphate}, Growth Factors {Demineralized Bon...
$ 3750